Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Gastroenterology | Gynecology | Nursing | Oncology | Journal

Back to Journal Articles

Sex Influences Survival in Esophageal Cancer

Last Updated: May 16, 2012.

 

Better esophageal cancer-specific survival for women with locoregional, metastatic cancer

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Sex is an independent prognostic factor for patients with locoregional esophageal cancer and metastatic esophageal cancer, according to a study published online May 14 in the Journal of Clinical Oncology.

WEDNESDAY, May 16 (HealthDay News) -- Sex is an independent prognostic factor for patients with locoregional esophageal cancer (LEC) and metastatic esophageal cancer (MEC), according to a study published online May 14 in the Journal of Clinical Oncology.

Pierre Bohanes, M.D., of the Keck School of Medicine in Los Angeles, and colleagues utilized Surveillance, Epidemiology, and End Results data from 1973 to 2007 to identify 13,603 patients with MEC and 26,848 patients with LEC to investigate the association between sex and survival in patients with esophageal cancer.

The researchers found that, in multivariate analysis, women with MEC and LEC had significantly longer esophageal cancer-specific survival (ECSS) than men (hazard ratio [HR], 0.949 [P = 0.029] and 0.920 [P < 0.001], respectively). There was no difference seen in ECSS for women and men with adenocarcinomas, after accounting for age and histology. Compared with men, women younger than 55 and aged 55 years or older with squamous LEC had longer ESCC (HR, 0.896 [P = 0.081] and 0.905 [P < 0.001]). Compared with men, women younger than age 55 years with squamous cell MEC also had longer ECSS (HR, 0.823; P = 0.011).

"Sex is an independent prognostic factor for patients with LEC or MEC," the authors write. "As secondary hypotheses, in comparison with men, women age 55 years or older with squamous cell LEC and women younger than age 55 years with squamous cell MEC have a significantly better outcome. These last two findings need further validation."

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Pazopanib Active in Metastatic Soft-Tissue Sarcoma Next: Repeated Revascularization Doesn't Aid High-Risk Patients

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.